Last updated: February 16, 2026
Product Overview
NDC 70069-0501 corresponds to Aflibercept (generic name), marketed under the brand name Eylea. It is an anti-VEGF (vascular endothelial growth factor) agent used primarily for treating ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Approved by the FDA, Eylea has demonstrated significant market penetration in ophthalmology.
Market Size and Growth Drivers
1. Market Scope
The global ophthalmic anti-VEGF market was valued at approximately $8.2 billion in 2022 and is projected to reach $12.5 billion by 2030, with a compound annual growth rate (CAGR) of approximately 6.3% [1].
2. Key Therapeutic Indications
- Wet age-related macular degeneration (AMD) — over 20 million cases worldwide [2]
- Diabetic macular edema (DME)
- Retinal vein occlusion (RVO)
These indications account for the majority of Eylea’s revenue, with AMD representing an estimated 70-75% of total ophthalmic VEGF therapy sales.
3. Competitive Landscape
Major competitors include:
- Ranibizumab (Lucentis)
- Bevacizumab (Avastin, off-label use)
Eylea holds over 70% market share in the U.S. due to its dosing frequency and comparable efficacy [3].
4. Market Dynamics
- Increasing aging populations drive demand.
- Rising diabetes prevalence expands DME indications.
- Innovations in delivery methods and extended dosing schedules improve adherence.
Pricing Analysis
1. Current Market Prices
- U.S. retail list price for a single 2 mg/0.2 mL vial of Eylea: approximately $1,850 [4].
- Average patient dose per injection: Once every 8 weeks after initial loading doses.
- Annual treatment cost estimates range from $22,200 to $27,600, depending on dosing frequency and reimbursement policies.
2. Reimbursement Landscape
- Medicare reimbursements for Eylea injections tend to cover around $1,600–$1,800 per injection.
- Commercial payers may negotiate discounts, impacting net prices.
3. Price Projections (Next 5 Years)
| Year |
Estimated List Price per Vial |
Projected Market Penetration |
Estimated Annual Revenue (USD billions) |
| 2023 |
$1,850 |
100% of current market |
$7.2 |
| 2024 |
$1,850 (stability) |
105% of 2023 |
$7.6 |
| 2025 |
$1,850 |
110% |
$8.1 |
| 2026 |
$1,900 (inflation adjustment) |
115% |
$8.9 |
| 2027 |
$1,950 |
120% |
$9.5 |
Note: Price adjustments account for inflation, competition, and negotiation pressure. Actual net prices may be lower due to discounts and rebates.
4. Impact of Biosimilars and Off-Label Alternatives
As biosimilars enter markets in Europe and potentially the U.S., they could erode prices, especially if approval processes and reimbursement policies favor lower-cost alternatives. Price erosion could reach 10-15% over the next five years.
Regulatory and Market Risks
- Patent Expirations: The primary patents for Eylea in the U.S. are set to expire around 2024–2025 [5], opening the market for biosimilar competition.
- Regulatory Approvals: Any delays in biosimilar approval or new indications could impact market share.
- Pricing and Reimbursement Dynamics: Growing pressure from payers to reduce costs could lead to aggressive rebates and discounts.
Key Market Entry Strategies
- Companies should monitor biosimilar approvals closely.
- Focus on generating real-world evidence for efficacy and safety.
- Explore differentiated delivery models to extend dosing intervals and reduce overall treatment costs.
Key Takeaways
- The global ophthalmic anti-VEGF market is poised to grow at 6.3% CAGR, reaching $12.5 billion by 2030.
- Eylea maintains a dominant market position with over 70% share in the U.S.
- Current list prices for Eylea are approximately $1,850 per vial, with annual treatment costs exceeding $22,000.
- Price projections indicate a steady increase through 2027, but biosimilar competition could lead to future price erosion.
- Patent expirations around 2024–2025 represent significant inflection points for pricing and market share.
FAQs
1. When will biosimilars for Eylea likely enter the U.S. market?
Biosignatures are expected to receive FDA approval starting from 2024, contingent on patent litigations and regulatory approvals.
2. How do discounts and rebates influence Eylea’s net price?
Negotiated rebates and discounts typically reduce the list price by 20–30%, varying by payer and policy.
3. What is the outlook for Eylea’s market share after patent expiration?
Market share is likely to decline as biosimilars enter, possibly losing 20–30% over the subsequent 2-3 years.
4. What factors could accelerate price declines for Eylea?
Increased biosimilar competition, payer pressure, and policy shifts favoring cost-effective alternatives.
5. Are there new indications or formulations expected to impact Eylea’s market?
Potential expansion into new indications or longer dosing formulations could stabilize revenue but are not imminent as of 2023.
References
[1] Research and Markets. "Global Ophthalmic Anti-VEGF Market Forecast," 2023.
[2] World Health Organization. "Age-Related Macular Degeneration," 2022.
[3] IQVIA. "Market Share and Competitive Analysis," 2022.
[4] GoodRx. "Current Price of Eylea," 2023.
[5] U.S. Patent and Trademark Office. "Patent Expiry Dates for Eylea," 2023.
